Vimarsana
Biggest News Aggregation in the World

Dose Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dose Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dose Management Today - Breaking & Trending Today

Biogen Inc.: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease - Vimarsana News

Biogen Inc.: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Published: June 10, 2024

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts

Source: finanznachrichten.de
Related Topics:
United KingdomHong KongUnited StatesSouth KoreaSaudi ArabiaGreat BritainChuck TrianoChristophera ViehbacherLinkedinand FacebookTsujim ProtofibrilsJack CoxHaruo NaitoJulie EdelmanDrug AdministrationEuropean UnionUnited Nations Sustainable Development Goals SdgsInvestor Relations DepartmentExchange CommissionEisai Co LtdNational Institutes Of HealthCommunications DepartmentWashington University School Of MedicineEisai Europe LtdNational Institute OnAlzheimer Clinical Trial Consortium
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status - Vimarsana News

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Published: May 15, 2024

TOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated the rolling submission of a Biologics License Application to the...

Source: marketscreener.com
Related Topics:
South KoreaUnited KingdomUnited StatesSaudi ArabiaHong KongGreat BritainChuck TrianoHaruo NaitoJack CoxJulie EdelmanTsujim ProtofibrilsEisai IncWashington University School Of MedicineNational Institute OnDrug AdministrationNational Institutes Of HealthEuropean UnionEisai Co LtdUnited Nations Sustainable Development Goals SdgsAlzheimer Network Trials UnitBiogen IncExchange CommissionInvestor Relations DepartmentPrnewswire Eisai Co LtdPublic Relations Department
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA - Vimarsana News

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Published: April 1, 2024

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Source: prnewswire.com
Related Topics:
Hong KongUnited StatesUnited KingdomSaudi ArabiaSouth KoreaGreat BritainLibby HolmanJack CoxChuck TrianoChristophera ViehbacherHaruo NaitoTsujim ProtofibrilsEisai IncPrnewswire Eisai Co LtdExchange CommissionEisai Co LtdEuropean UnionEisai Europe LtdDrug AdministrationBiogen IncUnited Nations Sustainable Development Goals SdgsPublic Relations DepartmentCommunications DepartmentInvestor Relations DepartmentSupplemental Biologics License Application
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease (CTAD) Conference -October 25, 2023 at 05:27 pm EDT - Vimarsana News

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer's Disease (CTAD) Conference -October 25, 2023 at 05:27 pm EDT

Published: October 25, 2023

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical...

Source: marketscreener.com
Related Topics:
United StatesSouth KoreaUnited KingdomNew ZealandGreat BritainActa PharmacolJack CoxChristophera ViehbacherTsujim ProtofibrilsHaruo NaitoChuck TrianoLibby HolmanCommunications DepartmentPublic Relations DepartmentEisai Europe LtdNational Institute OnNovel Subcutaneous AdministrationInvestor Relations DepartmentBiogen IncEisai Co LtdNational Institutes Of HealthAlzheimer Network Trials UnitWashington University School Of MedicineUnited Nations Sustainable Development Goals SdgsMinistry Of Health
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE - Vimarsana News

EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

Published: October 25, 2023

INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS 11% HIGHER, AND SIMILAR ARIA RATES TO IV 76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL...

Source: marketscreener.com
Related Topics:
United StatesSouth KoreaNew ZealandUnited KingdomGreat BritainChristophera ViehbacherTsujim ProtofibrilsChuck TrianoLibby HolmanHaruo NaitoJack CoxActa PharmacolInvestor Relations DepartmentNational Institute OnNovel Subcutaneous AdministrationEisai Europe LtdNational Institutes Of HealthEisai Co LtdBiogen IncCommunications DepartmentPublic Relations DepartmentAlzheimer Clinical Trial ConsortiumExchange CommissionAlzheimer AssociationMinistry Of Health